Xconomy.com publishes Nutter follow up on Acceleration conference, “2014 Trends in Early-Stage Life Sciences Investment” by Jeremy HalpernPrint PDF
“2014 Trends in Early-Stage Life Sciences Investment,” an article stemming from Nutter’s recent Acceleration/Early Stage Life Sciences Conference, was published by Xconomy.com on February 20 on its national front page. The article was authored by Jeremy Halpern, partner in the Business practice and the Director of Business Development for the Emerging Companies Group. He discusses how the Affordable Care Act (ACA), along with several other developments in the current venture funding environment, is beginning to radically reshape value creation in the life sciences and for biotechnology firms.
Jeremy goes on to discuss the challenges and opportunities for investment, providing suggestions for drilling down on specifics in milestone deals, and discussing the shift to a population-based approach to medicine and away from volume-based fee-for-service models. He cites speakers from the Acceleration conference, including Jonathan Norris, managing director for Silicon Valley Bank, Laurel Sweeney, senior director of health economics and reimbursement at Philips Healthcare, and Barbara Fox, founder of Avaxia Biologics.
To view the article, click here.